Protein C -1641A/-1654C haplotype is associated with organ dysfunction and the fatal outcome of severe sepsis in Chinese Han population

Human Genetics

Volumn 123, Issue 3, 2008, Pages 281-287

  Chen, Qi Xing ^a   Wu, Shui Jing ^a   Wang, Hai Hong ^a   Lv, Chen ^a   Cheng, Bao Li ^a   Xie, Guo Hao ^a   Fang, Xiang Ming ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ADENINE; CYTOSINE; GUANINE; THYMINE;

ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FATALITY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; SCORING SYSTEM; SEPSIS; SEQUENCE ANALYSIS;

ALLELES; CHINA; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); PROTEIN C; SEPSIS;

EID: 41149088131     PISSN: 03406717     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00439-008-0476-x     Document Type: Article

References (34)

1. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL (2005) Administration of drotrecogin alfa (activated) in early stage severe sepsis (ADDRESS) study group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332-1341
2. Aiach M, Nicaud V, Alhenc-Gelas M, Gandrille S, Arnaud E, Amiral J, Guize L, Fiessinger JN, Emmerich J (1999) Complex association of protein C gene promoter polymorphism with circulating protein C levels and thrombotic risk. Arterioscler Thromb Vasc Biol 19:1573-1576
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310
4. Annane D, Bellissant E, Cavaillon JM (2005) Septic shock. Lancet 365:63-78
5. Arcaroli J, Silva E, Maloney JP, He Q, Svetkauskaite D, Murphy JR, Abraham E (2006) Variant IRAK-1 haplotype is associated with increased nuclear factor-kappaB activation and worse outcomes in sepsis. Am J Respir Crit Care Med 173:1335-1341
6. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
7. Binder A, Endler G, Rieger S, Geishofer G, Resch B, Mannhalter C, Zenz W (2007) Protein C promoter polymorphisms associate with sepsis in children with systemic meningococcemia. Hum Genet 122:183-190
8. Brunkhorst F, Sakr Y, Hagel S, Reinhart K (2007) Protein C concentrations correlate with organ dysfunction and predict outcome independent of the presence of sepsis. Anesthesiology 107:15-23
9. Chen QX, Lv C, Huang LX, Cheng BL, Xie GH, Wu SJ, Fang XM (2007) Genomic variations within DEFB1 are associated with the susceptibility to and the fatal outcome of severe sepsis in Chinese Han population. Genes Immun 8:439-443
10. Cheng B, Xie G, Yao S, Wu X, Guo Q, Gu M, Fang Q, Xu Q, Wang D, Jin Y, Yuan S, Wang J, Du Z, Sun Y, Fang X (2007) Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 35:2538-2546
11. Cobb JP, O'Keefe GE (2004) Injury research in the genomic era. Lancet 363:2076-2083
12. Cohen J (2002) The immunopathogenesis of sepsis. Nature 420:885-891
13. Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR (2003) Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 31:12-19
14. Esmon CT (2004) Interactions between the innate immune and blood coagulation systems. Trends Immunol 25:536-542
15. Esmon CT (2005) The interactions between inflammation and coagulation. Br J Haematol 131:417-430
16. Fisher CJ Jr, Yan SB (2000) Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 28:S49-S56
17. Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF (2004) Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism (ISRCTN74215569). Crit Care 8:R82-R90
18. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31:1250-1256
19. Liaw PC, Esmon CT, Kahnamoui K, Schmidt S, Kahnamoui S, Ferrell G, Beaudin S, Julian JA, Weitz JI, Crowther M, Loeb M, Cook D (2004) Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 104:3958-3964
20. Lin MT, Albertson TE (2004) Genomic polymorphisms in sepsis. Crit Care Med 32:569-579
21. Macias WL, Nelson DR (2004) Severe protein c deficiency predicts early death in severe sepsis. Crit Care Med 32:S223-S228
22. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554
23. Mesters RM, Helterbrand J, Utterback BG, Yan B, Chao YB, Fernandez JA, Griffin JH, Hartman DL (2000) Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 28:2209-2216
24. Michalek J, Svetlikova P, Fedora M, Klimovic M, Klapacova L, Bartosova D, Elbl L, Hrstkova H, Hubacek JA (2007) Bactericidal permeability increasing protein gene variants in children with sepsis. Intensive Care Med 33:2158-2164
25. Mosnier LO, Zlokovic BV, Griffin JH (2007) The cytoprotective protein C pathway. Blood 109:3161-3172
26. Pinsky MR (2007) Genetics of individualizing patient care. Crit Care Med 35:287-290
27. Russell JA (2006) Management of sepsis. N Engl J Med 355:1699-1713
28. Sole X, Guino E, Valls J, Iniesta R, Moreno V (2006) SNPStats: A web tool for the analysis of association studies. Bioinformatics 22:1928-1929
29. Spek CA, Greengard JS, Griffin JH, Bertina RM, Reitsma PH (1995a) Two mutations in the promoter region of the human protein C gene both cause type I protein C deficiency by disruption of two HNF-3 binding sites. J Biol Chem 270:24216-24221
30. Spek CA, Koster T, Rosendaal FR, Bertina RM, Reitsma PH (1995b) Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. Arterioscler Thromb Vasc Biol 15:214-218
31. Stuber F (2001) Effects of genomic polymorphisms on the course of sepsis: Is there a concept for gene therapy? J Am Soc Nephrol 12(Suppl 17):S60-S64
32. Toltl LJ, Shin LY, Liaw PC (2007) Activated protein C in sepsis and beyond: Update 2006. Front Biosci 12:1963-1972
33. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D (2006) Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 34:344-353
34. Walley KR, Russell JA (2007) Protein C -1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis. Crit Care Med 35:12-17